Elke Seewaldt-Becker

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2014 · 393 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2013 · 375 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Tim Heise, Elke Seewaldt-Becker, Sreeraj Macha et al. · Diabetes Obesity and Metabolism · 2013 · 271 citations

Medicine, Pharmacokinetics, Pharmacology +15

A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo‐controlled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes

Ele Ferrannini, Leo Seman, Elke Seewaldt-Becker et al. · Diabetes Obesity and Metabolism · 2013 · 181 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study

Athanasios Manolis, John L. Reid, Dick de Zeeuw et al. · Journal of Hypertension · 2004 · 26 citations

Pharmacy, Pharmacology, Pharmacotherapy +17